{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:46Z","timestamp":1791472306470,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Validation of the new hemifacial spasm (HFS) questionnaire \u201cHFS score\u201d that captures both clinical (HFS clinical) and health-related quality of life (HRQOL) parameters (HFS subjective) in one tool and comparison with a global HRQOL questionnaire. Cross sectional, prospective validation study including 143 subjects (62 HFS patients and 81 healthy volunteers) from the University Eye Hospital Bonn. Patients were interviewed with the new HFS score and the SF-12 questionnaire prior to and 3\u00a0weeks after Botulinum neurotoxin A (BoNT-A) injection. All HRQOL-related questions (HFS subjective) were answered on a visual analogue scale (VAS) ranging from 0 (no complaints) to 100% (maximum complaints) by the patients themselves. Reproducibility was tested in a study extension with 10 patients by repeat interviews (telephone\/personal). The new HFS score questionnaire provided a reliable clinical assessment and demonstrated that BoNT-A therapy significantly reduced frequency and severity of eye and cheek spasms (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; Wilcoxon test). Relevant aspects of HRQOL of HFS patients were assessed with high accuracy and sensitivity. Significant improvements were achieved after BoNT-A injection in five out of eight HRQOL parameters (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.02; Wilcoxon test). Cronbach\u2019s alpha of 0.818 demonstrated good internal consistency. Telephone survey provided comparable results to personal interviews. This new sensitive and specific HFS score seems a reliable instrument to monitor BoNT therapy and customize it to the needs of the individual HFS patient\u2014in clinical studies and daily clinical practice.<\/jats:p>","DOI":"10.1007\/s00702-021-02343-x","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:06:11Z","timestamp":1620450371000},"page":"793-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters"],"prefix":"10.1007","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-114X","authenticated-orcid":false,"given":"Bettina","family":"Wabbels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yaqubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"2343_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ana.410320404","volume":"32","author":"CH Adler","year":"1992","unstructured":"Adler CH, Zimmerman RA, Savino PJ, Bernardi B, Bosley TM, Sergott RC (1992) Hemifacial spasm: evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol 32:502\u2013506","journal-title":"Ann Neurol"},{"key":"2343_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/archneur.1990.00530110095023","volume":"47","author":"RG Auger","year":"1990","unstructured":"Auger RG, Whisnant JP (1990) Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol 47:1233\u20131234","journal-title":"Arch Neurol"},{"key":"2343_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1553-2712.2001.tb01132.x","volume":"8","author":"PE Bijur","year":"2001","unstructured":"Bijur PE, Silver W, Gallagher EJ (2001) Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med 8:1153\u20131157","journal-title":"Acad Emerg Med"},{"key":"2343_CR4","volume-title":"Der SF-36 Fragebogen zum Gesundheitszustand (SF-36)-Handbuch f\u00fcr die deutschsprachige Fragebogenversion","author":"M Bullinger","year":"1998","unstructured":"Bullinger M, Kirchberger I (1998) Der SF-36 Fragebogen zum Gesundheitszustand (SF-36)-Handbuch f\u00fcr die deutschsprachige Fragebogenversion. Hogrefe, G\u00f6ttingen"},{"key":"2343_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1600-0404.1996.tb07053.x","volume":"94","author":"RS Chen","year":"1996","unstructured":"Chen RS, Lu CS, Tsai CH (1996) Botulinum toxin A injection in the treatment of hemifacial spasm. Acta Neurol Scand 94:207\u2013211","journal-title":"Acta Neurol Scand"},{"key":"2343_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.wneu.2017.08.044","volume":"107","author":"J Cheng","year":"2017","unstructured":"Cheng J, Lei D, Hui X, Zhang H (2017) Improvement of quality of life in patients with hemifacial spasm after microvascular decompression: a prospective study. World Neurosurg 107:549\u2013553","journal-title":"World Neurosurg"},{"key":"2343_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/eye.2009.192","volume":"24","author":"S Cillino","year":"2010","unstructured":"Cillino S, Raimondi G, Guepratte N, Damiani S, Cillino M, Di Pace F, Casuccio A (2010) Long-term efficacy of botulinum toxin of A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye 24:600\u2013607","journal-title":"Eye"},{"key":"2343_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1001\/archneur.59.3.418","volume":"59","author":"G Defazio","year":"2002","unstructured":"Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curr\u00e0 A, De Salvia R, Marchese R, Raineri R, Roselli F, Livrea P, Berardelli A (2002) Botulinum toxin a treatment for primary hemifacial spasm. Arch Neurol 59:418\u2013420","journal-title":"Arch Neurol"},{"key":"2343_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00839203","volume":"239","author":"JS Elston","year":"1992","unstructured":"Elston JS (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239:5\u20138","journal-title":"J Neurol"},{"key":"2343_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo controlled study. Neurology 37:616\u2013623","journal-title":"Neurology"},{"key":"2343_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/jnnp.64.6.751","volume":"64","author":"S Jitpimolmard","year":"1998","unstructured":"Jitpimolmard S, Tiamkao S, Laopaiboon M (1998) Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 64:751\u2013757","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl","key":"2343_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/PL00007813","volume":"248","author":"WH Jost","year":"2001","unstructured":"Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl):21\u201324","journal-title":"J Neurol"},{"key":"2343_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00181883","volume":"251","author":"R Laskawi","year":"1994","unstructured":"Laskawi R, Ellies M, Drobik C, B\u00e4tz A (1994) Botulinum toxin treatment in patients with hemifacial spasm. Eur Arch Otorhinolaryngol 251:271\u2013274","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2343_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000330396","volume":"90","author":"JA Lee","year":"2012","unstructured":"Lee JA, Jo KW, Kong D-S, Park K (2012) Using the new clinical grading scale for quantification of the severity of hemifacial spasm: correlations with a quality of life scale. Stereotact Funct Neurosurg 90:16\u201319","journal-title":"Stereotact Funct Neurosurg"},{"key":"2343_CR15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1212\/01.WNL.0000142080.85228.E8","volume":"63","author":"B Nilsen","year":"2004","unstructured":"Nilsen B, Le K-D, Dietrichs E (2004) Prevalence of hemifacial spasm in Oslo, Norway. Neurology 63:1532\u20131533","journal-title":"Neurology"},{"key":"2343_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3346\/jkms.1993.8.5.334","volume":"8","author":"YC Park","year":"1993","unstructured":"Park YC, Lim JK, Lee DK, Yi SD (1993) Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 8:334\u2013340","journal-title":"J Korean Med Sci"},{"key":"2343_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/1353-8020(95)00003-8","volume":"1","author":"N Poungvarin","year":"1995","unstructured":"Poungvarin N, Viriyavejakul A, Komoltri C (1995) Placebo-controlled double-blind cross-over study of botulinum A toxin in hemifacial spasm. Parkinsonism Relat Disord 1:85\u201388","journal-title":"Parkinsonism Relat Disord"},{"key":"2343_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.WNF.0000236771.77021.3C","volume":"30","author":"CR Rieder","year":"2007","unstructured":"Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J et al (2007) A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30:39\u201342","journal-title":"Clin Neuropharmacol"},{"key":"2343_CR19","first-page":"667","volume":"109","author":"C Rosenstengel","year":"2012","unstructured":"Rosenstengel C, Matthes M, Baldauf J, Fleck S, Schroeder H (2012) Hemifacial spasm: conservative and surgical treatment options. Dtsch Arztebl Int 109:667\u2013767","journal-title":"Dtsch Arztebl Int"},{"key":"2343_CR20","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s10072-019-03921-4","volume":"40","author":"N Tambasco","year":"2019","unstructured":"Tambasco N, Simoni S, Sacchini E, Eusebi P, Marsili E, Nigro P et al (2019) Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm. Neurol Sci 40:1887\u20131892","journal-title":"Neurol Sci"},{"key":"2343_CR21","first-page":"169","volume":"28","author":"EK Tan","year":"1999","unstructured":"Tan EK, Chan LL, Lim SH, Lim WE, Khoo JB, Tan KP (1999) Role of magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singap 28:169\u2013173","journal-title":"Ann Acad Med Singap"},{"key":"2343_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/qjmed\/95.8.493","volume":"95","author":"N Tan","year":"2002","unstructured":"Tan N, Chan L, Tan E (2002) Hemifacial spasm and involuntary facial movements. QJM 95:493\u2013500","journal-title":"QJM"},{"key":"2343_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2004.01.010","volume":"219","author":"EK Tan","year":"2004","unstructured":"Tan EK, Fook-Chong S, Lum SY, Lim E (2004) Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci 219:151\u2013155","journal-title":"J Neurol Sci"},{"key":"2343_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1136\/jnnp.2005.065656","volume":"76","author":"EK Tan","year":"2005","unstructured":"Tan EK, Fook-Chong S, Lum SY, Thumboo J (2005) Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. Neurol Neurosurg Psychiatry 76:1707\u20131710","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"2343_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jocn.2007.02.002","volume":"15","author":"T Tun\u00e7","year":"2008","unstructured":"Tun\u00e7 T, Cavdar L, Karada\u011f YS, Okuyucu E, Co\u015fkun O, Inan LE (2008) Differences in improvement between patients with idiopathic versus neurovascular hemifacial spasm after botulinum toxin treatment. J Clin Neurosci 15:253\u2013256","journal-title":"J Clin Neurosci"},{"key":"2343_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00702-011-0762-y","volume":"119","author":"B Wabbels","year":"2012","unstructured":"Wabbels B, Roggenk\u00e4mper P (2012) Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment. J Neural Transm 119:963\u2013980","journal-title":"J Neural Transm"},{"key":"2343_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00702-010-0546-9","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Jost WH, Roggenk\u00e4mper P (2011) Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm 118:925\u2013943","journal-title":"J Neural Transm"},{"key":"2343_CR28","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V","volume":"21","author":"A Wang","year":"1998","unstructured":"Wang A, Jankovic J (1998) Hemifacial spasm: clinical findings and treatment. Muscle Nerve 21:1740\u20131747","journal-title":"Muscle Nerve"},{"key":"2343_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1756285616682676","volume":"10","author":"D Weiss","year":"2017","unstructured":"Weiss D, Sturm J, Hieber L, B\u00f6rtlein A, Mayr I, Appy M, K\u00fchnler B, Buchthal J, Dippon C, Arnold G, W\u00e4chter T (2017) Health-related quality of life outcomes from botulinum toxin treatment in hemifacial spasm. Ther Adv Neurol Disord 10:211\u2013216","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"2343_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/mus.880150909","volume":"15","author":"DM Yoshimura","year":"1992","unstructured":"Yoshimura DM, Aminoff MJ, Tami TA, Scott AB (1992) Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 15(9):1045\u20131049","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-021-02343-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-021-02343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T10:08:46Z","timestamp":1623751726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-021-02343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2343"],"URL":"https:\/\/doi.org\/10.1007\/s00702-021-02343-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BW received travel grants and speaker honoraria from Desitin and Merz and research funding from Allergan and Merz, AY has no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Appr. Nr. 281\/13, University of Bonn, Bonn, Germany","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}